Non-Hodgkin Lymphoma
|
|
|
|
Here you will also find our relevant Book Store. Our book store consists of of books about non-Hodgkin lymphoma and cancer survival.
News sources are selected based on what information would be beneficial to the non-Hodgkin lymphoma patient, patient’s family, and oncologist. This is a news journal and it’s purpose is to provide current breakthroughs in terms of the biological or medical understanding of non-Hodgkin lymphoma.
This news journal is also about hope. The power of hope in healing and eliminating non-Hodgkin lymphoma is essential. On a personal note, my wife has had non-Hodgkin lymphoma now for thirteen years. According to doctors she should not be here today. She is currently living a full and productive life following a stem cell transplant a year and a half ago. Her stem cell transplant and subsequent new immune system, we hope will result in a complete abatement of her cancer. My wife’s stem cell transplant is one of the many options available for the non-Hodgkin lymphoma patient.
Breakthroughs in research on non-Hodgkin lymphoma are occurring frequently. The prudent non-Hodgkin lymphoma patient and family should keep up with the current understanding of treatments and cutting edge technologies. In many cases, the patient may even know more then the oncologist simply because the patient can concentrate on just his or her cancer, while the oncologists must deal with many types of cancer. Hence the need for this non-Hodgkin lymphoma news journal.
I initially put this journal together as a means to provide my wife and myself information on the latest cutting edge technologies for the treatment of non-Hodgkin lymphoma. I later decided, why not make it public, in order to provide other patients and families information on what I found. The news presented here comes from RSS feeds and will update automatically when new articles are available from the source. Book mark this site and view it daily to know about the most cutting edge treatment and research results about non-Hodgkin lymphoma
The Internet can be a powerful tool for the dissemination of information. For the non-Hodgkin lymphoma patient, living in the age of information technology brings benefits for knowledge growth which was unheard of fifteen years ago. Knowledge brings about understanding of cutting edge treatments. Most importantly, understanding creates hope for the non-Hodgkin lymphoma patient.
Here you also find a list of risk factors for the development of non-Hodgkin lymphoma, as well as statistics about this lymphoma cancer. Refer to the left navigation bar for these pages. We have also included some interesting and highly beneficial videos about non-Hodgkin lymphoma which includes stories of hope and inspiration. The following is our current video selections followed by the most current news about non-Hodgkin lymphoma. If the information presented here is helpful to the non-Hodgkins lymphoma patient, family and oncologist, then we have met our objective.
Non-Hodgkin Lymphoma - Videos
|
|
|
|
STOP! You must read this information before you decide about your cancer treatment. Over 350 non-toxic natural and alternative treatments that have helped thousands of people beat their cancer. Over 2,000 testimonials! Success rates for surgery, chemo and radiation revealed! Free information on financial and other help available. Download this set of 4 e-Books and Reports NOW. It could save your life.
The set of e-books and reports at www.naturalcancertreatments.com gives you EVERYTHING you need to know about natural and alternative treatments for cancer.
Non-Hodgkin’s Lymphoma - News
Clinical Care Options Oncology - Lymphoma
New treatment data and educational activities for Oncology and Hematology Clinicians
Lenalidomide Plus Low-Dose Dexamethasone Safe and Highly Active With or Without SCT in Newly Diagnosed MM
In patients with newly diagnosed multiple myeloma, lenalidomide plus low-dose dexamethasone had improved OS vs lenalidomide plus high-dose dexamethasone
Complete Remission Not Required for Azacitidine Survival Benefit in Patients With Higher-Risk MDS
Azacitidine associated with OS benefit over conventional care regimens in patients with higher-risk MDS who achieve hematologic improvement, PR, or CR
Expert Analysis: Lymphomas
A panel of experts comprising Alexandra M. Levine, MD; Carol S. Portlock, MD; and Julie M. Vose, MD, review highlighted studies on lymphomas presented at the 2007 ASH meeting.
Abbreviated Chemoimmunotherapy After R-CHOP Feasible in PET-Negative Patients With Limited-Stage DLBCL
Patients with limited-stage DLBCL who respond well to initial R-CHOP may not require subsequent radiation therapy
HyperCVAD Plus Rituximab Active in Newly Diagnosed MCL, Although Responses Not Durable and Regimen Associated With Considerable Toxicity
Despite high response rates of hyperCVAD plus rituximab in newly diagnosed MCL, response durability and toxicity remain key issues.
FIT Trial: 90Y-Ibritumomab Consolidation Therapy Superior to Observation in Advanced Follicular Lymphoma
90Y-ibritumomab tiuxetan consolidation therapy is highly efficacious for patients with advanced follicular non-Hodgkins lymphoma
PINNACLE Update: Bortezomib Responses Confirmed in Patients With Relapsed/Refractory MCL
Updated PINNACLE data: single-agent bortezomib efficacy confirmed in patients with relapsed/refractory MCLbbbbb
Pretransplant Rituximab Improves Posttransplantation Survival But Does Not Impair Engraftment Among Patients With DLBCL
PFS and OS improved among patients with DLBCL pretreated with rituximab before undergoing autologous hematopoietic stem cell transplantation.
Single-Agent Everolimus Active in Relapsed Aggressive Non-Hodgkins Lymphoma
Interim results from phase II trial of everolimus suggest possible role for mTOR inhibitors in relapsed, aggressive non-Hodgkins lymphoma
CNS Prophylaxis Not Protective Against CNS Relapse in Aggressive Non-Hodgkins Lymphoma With Bone Marrow Involvement
In a 20-year analysis from SWOG 8515, CNS prophylaxis did not reduce CNS relapse in patients with aggressive non-Hodgkins lymphoma.
Results of a Prospective Phase II Trial of Limited and Extended Rituximab in Nodular Lymphocyte-Predominant Hodgkins Disease
Extended vs limited rituximab therapy in patients with nodular lymphocyte-predominant Hodgkin lymphoma results in longer freedom from disease progression.
In Interim Analysis, Bendamustine Plus Rituximab Comparable to CHOP Plus Rituximab in First-Line Treatment of Patients With Indolent and Mantle Cell Lymphomas
Bendamustine plus rituximab showed response rates and PFS similar to CHOP plus rituximab as a first-line therapy for patients with indolent NHL and MCL in this first interim analysis of a German phase III noninferiority trial
Rituximab Followed by High-Dose Therapy With ASCT Effective as Salvage for Follicular Lymphoma
Salvage regimen containing rituximab followed by HDT-ASCT improved survival outcomes vs either alone in patients with follicular lymphoma after disease progression or relapse
Good Outcome With Intensive Immunochemotherapy With in Vivo Purged Stem Cell Support in Patients With Mantle Cell Lymphoma
Intensive immunochemotherapy induction, followed by high-dose chemotherapy and in vivo purged stem cell support, provides good long-term clinical outcomes in patients with mantle cell lymphoma
Novel Therapies for Waldenstroms Macroglobulinemia
Steven P. Treon, MD, MA, PhD, reviews current clinical trial data regarding the treatment of patients with Waldenstrms macroglobulinemia.
Follicular Lymphoma: State of the Art
Owen A. OConnor, MD, PhD, reviews current clinical trial data regarding the treatment of patients with follicular lymphoma.
The Evolving Role of Transplantation in Lymphoproliferative Malignancies
John P. Leonard, MD, reviews the use of stem-cell transplantation in the treatment of patients with Waldenstrms macroglobulinemia, follicular lymphoma, and mantle cell lymphoma.
Mantle Cell Lymphoma: State of the Art
Andre Goy, MD, reviews current clinical data regarding treatment of patients with mantle cell lymphoma.
Case Challenge: Treatment of Early-Stage CTCL in a 56-Year-Old Black Male Patient
Along with John A. Zic, MD, investigate the diagnosis of mycosis fungoides and review the treatment options available for patients with early-stage disease.
Rituximab resistance and the US clinical experience with Bendamustine
Jonathan W. Friedberg, MD explains some of the mechanisms of resistance to rituximab.
Clinical Issues and Future Directions in Hematologic Malignancies: Non-Hodgkins Lymphoma
Listen to Owen A. OConnor, MD, PhD, present the most up-to-date data from the 2006 hematology meeting in Orlando and highlight the clinical implications for improving outcomes in patients with non-Hodgkins lymphoma.
Non-Hodgkins Lymphoma - Google News
©2008 Google
Non-Hodgkins Lymphoma - Google News
A pitch to strike out cancer - Capital News 9
 Capital News 9 | A pitch to strike out cancer Capital News 9, NY - If they give it [Burkitt's non-Hodgkins lymphoma} to me then I'm gonna beat it. So basically I'm in it to win it, in that I'm gonna beat the fight against ... |
Mom, ex racked up DSS complaints - Boston Herald
 Boston Globe | Mom, ex racked up DSS complaints Boston Herald, United States - Jeremy, who went to live with his dad in March, was diagnosed in 2006 with non-Hodgkins lymphoma and given a 90 percent chance of survival. ... Video: Mom Charged With Denying Son Cancer Medication Autistic Boy Denied Chemotherapy By Mom Mum accused of denying chemo to critically ill son |
Crucial Factors In Lymphoma Development And Survival Discovered - Science Daily (press release)
Crucial Factors In Lymphoma Development And Survival Discovered Science Daily (press release) - Non-Hodgkins lymphoma is a cancer of lymphocytes, immune system cells known as T cells and B cells. About 66000 new cases of non-Hodgkins lymphoma are ... |
Battling non-Hodgkins lymphoma, local Grade 8 student will still ... - Standard Freeholder
Battling non-Hodgkins lymphoma, local Grade 8 student will still ... Standard Freeholder, Canada - It had to be by video from the Children's Hospital of Eastern Ontario, where she was receiving treatment for non-Hodgkins lymphoma. "Her last two lines were ... |
Cherokee Ballard named Woman of the Year for her battle with Non ... - Native Times
Cherokee Ballard named Woman of the Year for her battle with Non ... Native Times - "My Non-Hodgkins Lymphoma diagnosis was the most frightening thing I had ever dealt with." Since she has gone into remission in 2000, Ballard remains ... |
Riding for a cure - Kingston Reporter
Riding for a cure Kingston Reporter, MA - Team Greene captain Leigh Nali rides for his friend, Stephen Greene, who was diagnosed with non-Hodgkins lymphoma in 1996 and lost his battle with cancer ... |
fighting spirit - Irish Independent
fighting spirit Irish Independent, Ireland - By an extraordinary coincidence, his GP was away and the locum was a young doctor who had just spent time in a ward dealing with non-Hodgkins lymphoma. ... |
Health, Hope, Heroes: Larry's Story - KCCI.com
Health, Hope, Heroes: Larry's Story KCCI.com, IA - I was diagnosed with Non Hodgkins Lymphoma in March of 2007. I went to John Stoddard Cancer Center the day after my initial diagnosis. ... |
Do Reduced-intensity Allogeneic Stem Cell Transplants Have ... - Cancer Consultants
Do Reduced-intensity Allogeneic Stem Cell Transplants Have ... Cancer Consultants, ID - Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with follicular non-Hodgkins lymphoma (FL) beyond first ... |
Leukemia & Lymphoma Society raises more than $200000 - Denver Post
Leukemia & Lymphoma Society raises more than $200000 Denver Post, CO - ... a Leukemia & Lymphoma Society board member who lost her young son, Blake, to non- Hodgkins Lymphoma; Elizabeth Byrnes Crony, a former vice president at ... |
For more news about Non-Hodgkin Lymphoma go to MedWorm: Non-Hodgkin Lymphoma. This page is more technical and is most likely more useful to oncologists. But for patients who want to know about cutting edge treatments and research for NHL, this page will also be useful. View this page frequently because it is updated daily.
Powered by FirstRSS Plugin
